Do Herbal Agents Have a Place in the Treatment of Sleep Problems in Long-Term Care?

Journal of the American Medical Directors Association

Volumn 8, Issue 4, 2007, Pages 248-252

  Shimazaki, Mark ^a   Martin, Jennifer L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Alternative therapies; elderly; insomnia; sleep

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HERBACEOUS AGENT; MELATONIN; NATURAL PRODUCT; OXAZEPAM; PLACEBO; RAMELTEON; VALERIAN;

ARTICLE; CLINICAL TRIAL; CONSENSUS; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; INSOMNIA; LONG TERM CARE; META ANALYSIS; POLYSOMNOGRAPHY; REM SLEEP; RISK ASSESSMENT; SLEEP DISORDER; SYSTEMATIC REVIEW;

EID: 34247863900     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.11.001     Document Type: Article

References (40)

1. Lichstein K.L., Durrence H.H., Riedel B.W., Taylor D.J., and Bush A.J. Epidemiology of sleep (2004), Lawrence Erlbaum Associates, Mahwah, NJ
2. Bliwise D.L. Review: Sleep in normal aging and dementia. Sleep 16 (1993) 40-81
3. Bliwise D.L. Normal aging. In: Kryger M.H., Roth T., and Dement W.C. (Eds). Principles and Practice of Sleep Medicine (1994), W.B. Saunders Company, Philadelphia
4. Bliwise D.L. Normal aging. In: Kryger M.H., Roth T., and Dement W.C. (Eds). Principles and Practice of Sleep Medicine. 4th ed. (2004), Elsevier Saunders, Philadelphia 24-38
5. Martin J.L., Webber A.P., Alam T., et al. Daytime sleeping, sleep disturbance and circadian rhythms in nursing home residents. Am J Geriatr Psychiatry 14 (2006) 121-129
6. Voyer P., Verreault R., Mengue P.N., et al. Prevalence of insomnia and its associated factors in elderly long-term care residents. Arch Gerontol Geriatr 42 (2006) 1-20
7. National Sleep Foundation. 2003 "Sleep in America" poll. Available at: www.sleepfoundation.org/polls/2003SleepPollExecutiveSumm.pdf. Accessed August 12, 2005.
8. Grzywacz J.G., Lang W., Suerken C., et al. Age, race and ethnicity in the use of complementary and alternative medicine for health self-management. J Aging Health 17 (2005) 547-572
9. Ness J., Cirillo D.J., Weir D.R., et al. Use of complementary medicine in older Americans: Results from the health and retirement study. Gerontologist 45 (2005) 516-524
10. Valerian: product review. Available at: www.consumerlab.com. Accessed August 12, 2005.
11. Avidan A.Y., Fries B.E., James M.L., et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 53 (2005) 955-962
12. Ray W.A., Thapa P.B., and Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 48 (2000) 682-685
13. Granek E., Baker S.P., Abbey H., et al. Medications and diagnoses in relation to falls in a long-term care facility. J Am Geriatr Soc 35 (1987) 503-511
14. Schneeweiss S., and Wang P.S. Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information. J Am Geriatr Soc 53 (2005) 948-954
15. National Center for Complimentary and Alternative Medicine. The use of complementary and alternative medicine in the United States (2004), National Institutes of Health, Washington DC Ref Type: Generic
16. Santos M.S., Ferreira F., Cunha A.P., et al. Synaptosomal GABA release as influenced by valerian root extract-involvement of the GABA carrier. Arch Int Pharmacodyn Ther 327 (1994) 220-231
17. Dietz B.M., Mahady G.B., Pauli G.F., et al. Valerian extract and valerenic acid are partial agonists of the 5-HT[5a] receptor in vitro. Brain Res Mol Brain Res 138 (2005) 191-197
18. Schumacher B., Scholle S., Holzl J., et al. Lignans isolated from valerian: Identification and characterization of a new olivil derivative with partial agonistic activity at A[1] adenosine receptors. J Nat Prod 65 (2002) 1479-1485
19. Schulz H., Stolz C., and Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: A pilot study. Pharmacopsychiatry 27 (1995) 147-151
20. Vorbach E.U., Gortelmeyer R., and Bruning J. Therapie von insomnien: wirksamkeit und vertraglichkeit eines baldranpraparats (Therapy for insomniacs: effectiveness and tolerance of valerian preparations). Psychopharmakotherapie 3 (1996) 109-115
21. Zhdanova I.V., Wurtman R.J., Regan M.M., et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 86 (2001) 4727-4730
22. Singer C., Tractenberg R.E., Kaye J., et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26 (2003) 893-901
23. Kamm-Kohl A.V., Jansen W., and Brockmann P. Moderne baldriantherapie gegen vervose storungen im semium (Modern valerian therapy for nervous disorders in old age). Med Welt 35 (1984) 1450-1454
24. Valerian officinalis. (monograph). Alternative Medicine Reviews 9 (2004) 438-441
25. Stevinson C., and Ernst E. Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Med 1 (2000) 91-99
26. Dorn M. [Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study]. Forsch Komplementarmet Klass Naturheikd 7 (2000) 79-84 German
27. Ziegler G., Ploch M., Miettenen-Baumann A., et al. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia-a randomized, double-blind, comparative clinical study. Eur J Med Res 7 (2002) 480-486
28. Donath F., Quispe S., Diefenbach K., et al. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33 (2000) 47-53
29. Poyares D.R., Guilleminault C., Ohayon M.M., et al. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal?. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 539-545
30. Medline plus. Drugs, supplements, and herbal Information. Available at: www.nlm.nih.gov/medlineplus/druginformation.html. Accessed October 7, 2006.
31. Arendt J. Chronobiology of melatonin. ISI Atlas Sci-Pharmacol 1 (1987) 257
32. Almeida Montes L.G., Ontiveros Uribe M.P., Cortes Sotres J., et al. Treatment of primary insomnia with melatonin: A double-blind, placebo-controlled, crossover study. J Psychiatr Neurosci 28 (2002) 191-196
33. Olde Rikkert M.G., and Rigaud A.S. Melatonin in elderly patients with insomnia. A systematic review. Z Gerontol Geriatr 34 (2001) 491-497
34. Brzezinski A., Vangel M.G., Wurtman R.J., et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9 (2005) 41-50
35. Claustrat B., Brun J., and Chazot G. The basic physiology and pathophysiology of melatonin. J Sleep Res 9 (2004) 11-24
36. Pires M.L., Benedito-Silva A.A., Pinto L., et al. Acute effects of low doses of melatonin on the sleep of young healthy subjects. J Pineal Res 31 (2001) 326-332
37. Kato K., Hirai K., Nishiyama K., et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48 (2005) 301-310
38. Zemlan F.P., Mulchahey J., Scharf M.B., et al. The efficacy and safety of the melatonin agonist [beta]-methyl-6-chloromelatonin in primary insomnia: A randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 66 (2005) 384-390
39. Roth T., Seiden D., Sainati S., et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7 (2006) 312-318
40. Natural medicines comprehensive database. Available at: www.naturaldatabase.com. Accessed October 18, 2006.